View DividendThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMedcomtech マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報Juan Sagales Manas最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.すべての更新を表示Recent updatesNew Risk • Nov 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€5.38m market cap, or US$5.76m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).分析記事 • Oct 18Returns Are Gaining Momentum At Medcomtech (BME:MED)What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...分析記事 • Aug 26Many Still Looking Away From Medcomtech, S.A. (BME:MED)Medcomtech, S.A.'s ( BME:MED ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: €24.9m (up 9.2% from FY 2021). Net loss: €1.59m (loss widened 22% from FY 2021).分析記事 • Mar 21Returns At Medcomtech (BME:MED) Are On The Way UpFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Dec 06Medcomtech (BME:MED) Is Experiencing Growth In Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Aug 16Investors Will Want Medcomtech's (BME:MED) Growth In ROCE To PersistTo find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Apr 09Medcomtech (BME:MED) Is Looking To Continue Growing Its Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...分析記事 • May 17Here's Why Medcomtech (BME:MED) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improved over the past weekAfter last week's 20% share price gain to €1.20, the stock is trading at a trailing P/E ratio of 3.7x, up from the previous P/E ratio of 3.1x. This compares to an average P/E of 26x in the Healthcare industry in Europe. Total return to shareholders over the past three years is a loss of 64%.Is New 90 Day High Low • Feb 12New 90-day high: €0.97The company is up 32% from its price of €0.74 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period.Is New 90 Day High Low • Jan 21New 90-day high: €0.78The company is up 5.0% from its price of €0.74 on 23 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period.Is New 90 Day High Low • Jan 05New 90-day low: €0.56The company is down 24% from its price of €0.74 on 07 October 2020. The Spanish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 11New 90-day low: €0.69The company is down 4.0% from its price of €0.71 on 11 September 2020. The Spanish market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period.分析記事 • Nov 30Should Weakness in Medcomtech, S.A.'s (BME:MED) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 8.3% over the past three months, it is easy to disregard Medcomtech (BME:MED). But if you pay...お知らせ • Jul 18Medcomtech, S.A. Auditor Raises 'Going Concern' DoubtMedcomtech, S.A. filed its Annual on Jul 06, 2020 for the period ending Dec 31, 2019. In this report its auditor, Deloitte & Touche LLP, gave a qualified opinion expressing doubt that the company can continue as a going concern.CEOJuan Sagales Manas no data在職期間Mr. Juan Sagales Manas serves as the Chairman of the Board, Chief Executive Officer and President at Medcomtech S.A.View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/13 08:58終値2024/01/15 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medcomtech, S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael Thomas CooperEdison Investment Research
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • Nov 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€5.38m market cap, or US$5.76m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
分析記事 • Oct 18Returns Are Gaining Momentum At Medcomtech (BME:MED)What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
分析記事 • Aug 26Many Still Looking Away From Medcomtech, S.A. (BME:MED)Medcomtech, S.A.'s ( BME:MED ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...
Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: €24.9m (up 9.2% from FY 2021). Net loss: €1.59m (loss widened 22% from FY 2021).
分析記事 • Mar 21Returns At Medcomtech (BME:MED) Are On The Way UpFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Dec 06Medcomtech (BME:MED) Is Experiencing Growth In Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Aug 16Investors Will Want Medcomtech's (BME:MED) Growth In ROCE To PersistTo find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Apr 09Medcomtech (BME:MED) Is Looking To Continue Growing Its Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
分析記事 • May 17Here's Why Medcomtech (BME:MED) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improved over the past weekAfter last week's 20% share price gain to €1.20, the stock is trading at a trailing P/E ratio of 3.7x, up from the previous P/E ratio of 3.1x. This compares to an average P/E of 26x in the Healthcare industry in Europe. Total return to shareholders over the past three years is a loss of 64%.
Is New 90 Day High Low • Feb 12New 90-day high: €0.97The company is up 32% from its price of €0.74 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Jan 21New 90-day high: €0.78The company is up 5.0% from its price of €0.74 on 23 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Jan 05New 90-day low: €0.56The company is down 24% from its price of €0.74 on 07 October 2020. The Spanish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 11New 90-day low: €0.69The company is down 4.0% from its price of €0.71 on 11 September 2020. The Spanish market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period.
分析記事 • Nov 30Should Weakness in Medcomtech, S.A.'s (BME:MED) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 8.3% over the past three months, it is easy to disregard Medcomtech (BME:MED). But if you pay...
お知らせ • Jul 18Medcomtech, S.A. Auditor Raises 'Going Concern' DoubtMedcomtech, S.A. filed its Annual on Jul 06, 2020 for the period ending Dec 31, 2019. In this report its auditor, Deloitte & Touche LLP, gave a qualified opinion expressing doubt that the company can continue as a going concern.